Quick Answer
GYRE THERAPEUTICS, INC. reported Stockholders Equity of $106.03 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $106.03M | +67.5% |
| 2024 | $63.32M | +500.0% |
| 2023 | -$15.83M | -137.2% |
| 2022 | $42.52M | +3.5% |
| 2021 | $41.09M | -46.0% |
| 2020 | $76.07M | +11.3% |
| 2019 | $68.34M | -43.0% |
| 2018 | $119.94M | +289.8% |
| 2017 | $30.77M | +91.5% |
| 2016 | $16.07M | -48.9% |
| 2015 | $31.43M | +128.7% |
| 2014 | -$109.35M | -6.2% |
| 2013 | -$103.01M | -10.4% |
| 2012 | -$93.34M | -153.6% |
| 2011 | $174.29M | +89.8% |
| 2010 | $91.85M | +33.1% |
| 2009 | $68.99M | +20.2% |
| 2008 | $57.37M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $101.92M | +61.3% | +10.8% |
| June 30, 2025 | $92.03M | +52.5% | +35.1% |
| March 31, 2025 | $68.12M | +20.3% | +7.6% |
| December 31, 2024 | $63.32M | +500.0% | +0.2% |
| September 30, 2024 | $63.18M | +1696.4% | +4.7% |
| June 30, 2024 | $60.35M | +313.1% | +6.6% |
| March 31, 2024 | $56.64M | +318.2% | +457.8% |
| December 31, 2023 | -$15.83M | +27.0% | -550.0% |
- GYRE THERAPEUTICS, INC. showed an increase of +67.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, GYRE THERAPEUTICS, INC.’s stockholders equity has grown by 84.8% (from $57.37 million to $106.03 million).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: